Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
Public ClinicalTrials.gov record NCT02899052. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part 4 of this study is currently enrolling.
Study identification
- NCT ID
- NCT02899052
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 19, 2017 (Actual)
- Primary completion
- Jun 2027 (Estimated)
- Completion
- Jun 2027 (Estimated)
- Last update posted
- Aug 5, 2025
2017 – 2027
United States locations
- U.S. sites
- 18
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham - Main /ID# 151405 | Birmingham | Alabama | 35233 | — |
| University of Arkansas for Medical Sciences /ID# 151399 | Little Rock | Arkansas | 72205 | — |
| Memorial Healthcare System /ID# 224862 | Hollywood | Florida | 33021-3513 | — |
| Winship Cancer Institute of Emory University /ID# 161710 | Atlanta | Georgia | 30322 | — |
| The University of Chicago Medical Center /ID# 151395 | Chicago | Illinois | 60637-1443 | — |
| Indiana Blood & Marrow Transpl /ID# 218862 | Indianapolis | Indiana | 46237 | — |
| Duplicate_University of Kentucky Chandler Medical Center /ID# 151407 | Lexington | Kentucky | 40536 | — |
| Central Maine Medical Center /ID# 218856 | Lewiston | Maine | 04240 | — |
| Duplicate_University of Maryland School of Medicine /ID# 159721 | Baltimore | Maryland | 21201-1544 | — |
| Oncology Hematology Associates (OHA) - Springfield /ID# 218855 | Springfield | Missouri | 65807-5287 | — |
| Washington University-School of Medicine /ID# 222651 | St Louis | Missouri | 63110 | — |
| Duke Cancer Center /ID# 162062 | Durham | North Carolina | 27710-3000 | — |
| University of Pennsylvania /ID# 151768 | Philadelphia | Pennsylvania | 19104-5502 | — |
| University of Texas Southwestern Medical Center /ID# 218336 | Dallas | Texas | 75390-7208 | — |
| Baylor Scott & White Medical Center- Temple /ID# 218252 | Temple | Texas | 76508-0001 | — |
| University of Utah /ID# 151397 | Salt Lake City | Utah | 84112-5500 | — |
| Duplicate_VA Puget Sound Healthcare Syst /ID# 155369 | Seattle | Washington | 98108 | — |
| Aurora Health Care, Aurora Cancer Center /ID# 209612 | Wauwatosa | Wisconsin | 53226-3436 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02899052, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 5, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02899052 live on ClinicalTrials.gov.